Bridging the Cultural Divide Between Healthcare and Healthtech

by | Dec 10, 2019 | Healthcare, Healthtech | 0 comments

Bridging the Cultural Divide Between Healthcare and Healthtech 1

From Healthcare to Healthtech

Jill Hagenkord talks about her transition from Healthcare to Healthtech and shares the lessons she learned. In this podcast Jill shares some of the cultural differences she observed between the two industries and the ways that healthtech companies can collaborate with healthcare experts to create clinically and commercially viable health products that can scale.

jill hagenkord

Jill Hagenkord, MD

MDisrupt Guest Author

Jill is a board-certified pathologist with subspecialty boards in molecular genetic pathology and a fellowship in pathology/oncology informatics. She brings expertise in health product strategy, coding, coverage, reimbursement, medical and regulatory affairs, health policy, clinical laboratory medicine, population health, provider education and patient engagement.

Accessing the self-insured employer channel correctly takes special expertise. If this channel is key to your commercial strategy, talk to us—we can help.


Submit a Comment

Your email address will not be published. Required fields are marked *


Join Our Mission.

Become an MDisruptor.

At MDisrupt, we match practicing health industry professionals to healthtech companies seeking to build clinically and commercially viable products. We handle the details, allowing you to do what you do best

Check out these related posts

MDisrupt One Year On—A Year of Transformation

MDisrupt One Year On—A Year of Transformation

MDisrupt One Year On – A Year of Learning and Transformation

The only constant in life is change. And nowhere is that more true than in your first year as a start-up.

As many of you know, MDisrupt was founded a year ago because we believed the healthtech world was lacking “medical diligence”. We believed this was the missing link in the market and the reason why so many healthtech startups were stumbling on the path to successfully commercializing their health products. We created MDisrupt to help others avoid becoming the next Theranos, or uBiome – and to help divert healthtech companies away from criticisms of attempting to dupe consumers, skipping a few steps on the road to evidence generation, or taking the wrong regulatory path.

read more
Share This